Since December of 2019, the novel coronavirus (2019-nCoV) outbreak continues to grow in China and countries such as Singarpore, Japan, UK, the US, Germany.
Source: Xinhuanet.com
Up till Apr.27 24:00 p.m. (BJS):
| Location | Cumulative Cases | Deaths | Cured Cases |
| China | 82836 | 4633 | 77555 |
| Hubei | 68128 | 4512 | 63616 |
| Wuhan | 50333 | 3869 | 46464 |
| Shanghai | 642 | 7 | 568 |
| Location | Cumulative Cases | Deaths | Newly Confirmed Cases |
| Out of China | 2830916 | 197903 | 45745 |
Updated News on the Novel Coronavirus
Another inactivated virus vaccine under investigation by Beijing Kexing Zhongwei was approved for clinical use on April 13, and the COVID-19 inactivated vaccine for clinical trials has passed the inspection of the Chinese Procuratorate, and the clinical trials have been initiated. The recent research vaccine data published by the Chinese Academy of Medical Sciences in BioRxiv is Kexing's research vaccine, and it is expected that this vaccine will be used in human clinical manifestations.
On April 12, the new coronavirus inactivated vaccine declared by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology of the Chinese Academy of Sciences was approved by the State Drug Administration for clinical trials, and Phase I / II clinical trials will be combined. This is the world's first inactivated new coronavirus vaccine that has received clinical trial approval.
On March 18, the recombinant new coronavirus vaccine (adenovirus vector) ("Ad5-nCoV") developed by Kang Xinuo and the Academy of Military Medical Sciences was approved for clinical use. This is the first new crown vaccine to enter clinical trials in China.
On April. 3th, according to Sciencedirect, Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in...
Read More